Microdosing: Applications, Medications, and Risks
Open Learning
On Demand
20
USD
Online
Focus:
Psychedelics
Description
Explore what's known and what's not when it comes to microdosing psychedelics
Microdosing or the practice of taking very low doses of psychedelics on a regular basis, has become popular and touted to help in a variety of situations including improvements in mental health or as a tool to help taper psychiatric medications. But is it true?
Can microdosing improve mood, reduce anxiety, as well as help persons taper antidepressants or other medications?
Some survey research has reported seemingly remarkable results, while many clinical trials have failed to demonstrate significant benefits. The jury is largely still out on microdosing as the evidence base is young and evolving, yet it’s fair to say that at this point we have enough data to conclude that microdosing is no ‘placebo’.
So what is it? What do we know? And what is still to be discovered?
In this workshop we'll explore the current state of evidence regarding microdosing and the plausibility of microdosing practices to aid in tapering psychiatric medications such as selective serotonin reuptake inhibitors (SSRIs).
The official objectives are to:
Define microdosing, how it could work, popular current regimens, and potential applications
Compare and contrast microdosing to use of SSRIs and discuss if microdosing could help persons taper antidepressants
List reported side effects of microdosing and outline theoretical risks associated with chronic and long-term use of psychedelics
Summarize existing clinical research as it relates to microdosing
Microdosing or the practice of taking very low doses of psychedelics on a regular basis, has become popular and touted to help in a variety of situations including improvements in mental health or as a tool to help taper psychiatric medications. But is it true?
Can microdosing improve mood, reduce anxiety, as well as help persons taper antidepressants or other medications?
Some survey research has reported seemingly remarkable results, while many clinical trials have failed to demonstrate significant benefits. The jury is largely still out on microdosing as the evidence base is young and evolving, yet it’s fair to say that at this point we have enough data to conclude that microdosing is no ‘placebo’.
So what is it? What do we know? And what is still to be discovered?
In this workshop we'll explore the current state of evidence regarding microdosing and the plausibility of microdosing practices to aid in tapering psychiatric medications such as selective serotonin reuptake inhibitors (SSRIs).
The official objectives are to:
Define microdosing, how it could work, popular current regimens, and potential applications
Compare and contrast microdosing to use of SSRIs and discuss if microdosing could help persons taper antidepressants
List reported side effects of microdosing and outline theoretical risks associated with chronic and long-term use of psychedelics
Summarize existing clinical research as it relates to microdosing
